Currently, the decreasing number of patients with CKD stage 4/5 is believed to be associated with antiproteinuric effects of the TTR stabilizer tafamidis and TTR silencing therapy patisiran.42,43 In mutations with kidney involvement (Table 2), regular assessment of urine albumin–creatinine ratio and kidney function are recommended, even in asymptomatic carriers.44 The disease-modifying therapies in ATTR amyloidosis should be maintained even in dialysis because the systemic disease will progress. This evidence concerns the gene TTR and chronic kidney disease.